Sarepta Therapeutics (LTS:0L35) Cyclically Adjusted FCF per Share: $-5.46 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0L35 Sarepta Therapeutics Inc LTS:0L35
51 GF Score
Price $22.24
GF Value $107.78
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sarepta Therapeutics Cyclically Adjusted FCF per Share?

Sarepta Therapeutics LTS:0L35 -3.60% 51 Cyclically Adjusted FCF per Share is $-5.46 as of Jun. 2026. GuruFocus rates LTS:0L35 with a GF Score™ of 51/100 and a GF Value™ of $107.78 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Sarepta Therapeutics's adjusted free cash flow per share for the three months ended in Jun. 2026 was $1.864. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-5.46 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -3.70% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -8.30% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Sarepta Therapeutics was 13.00% per year. The lowest was -16.60% per year. And the median was -4.00% per year.

As of today (2026-09-06), Sarepta Therapeutics's current stock price is $22.24. Sarepta Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was $-5.46. Sarepta Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Sarepta Therapeutics  (LTS:0L35) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Sarepta Therapeutics Cyclically Adjusted FCF per Share Related Terms


Sarepta Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Sarepta Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics Cyclically Adjusted FCF per Share Chart

Sarepta Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.55 -4.88 -5.58 -5.57 -5.62

Sarepta Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.89 -5.57 -5.62 -5.63 -5.46

LTS:0L35 vs AUPH, PVLA, MLYS: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Sarepta Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sarepta Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


LTS:0L35
51GF Score
Sarepta Therapeutics Inc LTS:0L35
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sarepta Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sarepta Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.864/333.9520*333.9520
=1.864

Current CPI (Jun. 2026) = 333.9520.

Sarepta Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -1.280 241.428 -1.771
201612 -1.547 241.432 -2.140
201703 -1.135 243.801 -1.555
201706 -1.608 244.955 -2.192
201709 -1.067 246.819 -1.444
201712 -0.558 246.524 -0.756
201803 -0.751 249.554 -1.005
201806 -1.937 251.989 -2.567
201809 -2.031 252.439 -2.687
201812 -2.040 251.233 -2.712
201903 -2.265 254.202 -2.976
201906 -1.294 256.143 -1.687
201909 -1.036 256.759 -1.347
201912 -2.428 256.974 -3.155
202003 8.094 258.115 10.472
202006 -1.626 257.797 -2.106
202009 -3.357 260.280 -4.307
202012 -2.574 260.474 -3.300
202103 -2.536 264.877 -3.197
202106 -1.443 271.696 -1.774
202109 -1.672 274.310 -2.036
202112 -0.394 278.802 -0.472
202203 -1.223 287.504 -1.421
202206 -0.867 296.311 -0.977
202209 -0.849 296.808 -0.955
202212 -1.145 296.797 -1.288
202303 -2.483 301.836 -2.747
202306 -1.580 305.109 -1.729
202309 -1.749 307.789 -1.898
202312 -0.710 306.746 -0.773
202403 -2.871 312.332 -3.070
202406 -0.143 314.175 -0.152
202409 -1.075 315.301 -1.139
202412 0.406 315.605 0.430
202503 -6.464 319.799 -6.750
202506 2.155 322.561 2.231
202509 -0.432 324.800 -0.444
202512 1.216 324.054 1.253
202603 -1.688 330.213 -1.707
202606 1.864 333.952 1.864

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-5.46 mean?
Sarepta Therapeutics (LTS:0L35) has a Cyclically Adjusted FCF per Share of $-5.46 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' Cyclically Adjusted FCF per Share too high?
Sarepta Therapeutics' current Cyclically Adjusted FCF per Share is $-5.46. Overall, Sarepta Therapeutics has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Cyclically Adjusted FCF per Share compare to AUPH and PVLA?
Sarepta Therapeutics' Cyclically Adjusted FCF per Share of $-5.46 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Cyclically Adjusted FCF per Share is $-5.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (LTS:0L35) is currently considered Possible Value Trap. The stock's GF Value™ is $107.78, compared to a current price of $22.24 — trading 79.4% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $-5.46. Sarepta Therapeutics' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Sarepta Therapeutics (LTS:0L35), the current Cyclically Adjusted FCF per Share is $-5.46 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sarepta Therapeutics (LTS:0L35) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of $22.24 is trading 79.4% below its estimated GF Value™ of $107.78. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for LTS:0L35:

  • Cyclically Adjusted FCF per Share: $-5.46
  • GF Value™: $107.78 vs. price of $22.24 (79.4% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the LTS:0L35 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
51GF Score

Get the complete analysis for LTS:0L35

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.24
Price
$107.78
GF Value